Reducing cardiovascular burden in psoriasis patients by using specific therapies – How close are we?

Abstract

Psoriasis is a chronic, systemic inflammatory disease that has gained popularity among scientific research from many promising perspectives on diagnosis and treatment. Individuals with psoriasis associate numerous comorbidities and have many predisposing factors in common especially with heart disease. Based on this, researchers tried to identify the common pathogenic mechanisms, the impact of risk factors on both pathologies, the influence of one disease on the another as well as the impact of novel therapies used in psoriasis on cardiovascular system, in order to improve the prognosis and quality of life of these patients. Areas of uncertainty. Pathogenic mechanisms involved both in psoriasis and atherosclerotic disease are not fully understood, especially in relationship with actual treatment strategies and their impact on prognosis. The purpose of this descriptive review is to summarize the latest available data, to see whether current treatment strategies of psoriatic disease should take into consideration the risk of cardiovascular disease (CVD) when one drug should be chosen at the expense of another. Data sources. Literature research was performed using electronic database (PubMed, Cochrane Library and Web of Science) between January 2010 and June 2022. We used different keywords and MeSH terms to generate the most relevant results regarding psoriasis and cardiovascular disease. First, we evaluated the titles and abstracts of the articles and we excluded papers that didn’t met selection criteria.

Keywords

• psoriasis
• cardiovascular disease
• atherosclerosis
• coronary artery disease
• myocardial infarction
• methotrexate
• biologic therapy